Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
Date:11/1/2013

NANJING, China, Nov. 1, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.845.675.0437China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q3 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 94745140

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.855.452.5696United States toll:+1.646.254.3697The passcode for replay participants is 94745140. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Vivien LiangCindy ZhengSimcere Pharmaceutical GroupBrunswick GroupTel: 86-25-8556-6666*8857Tel: 1-212-333-3810In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
3. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
4. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Boda
5. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
6. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
8. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
9. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
10. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
11. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... healthcare industry, ranked among the top five firms in the “2015/2016 Best in ... Implementation Support and Staffing. KLAS is a research and insights firm on a ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... and Reconstructive Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and ... surgery . Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
Breaking Medicine News(10 mins):